Gateway Genomics→Myriad Genetics
Acquisition · Cash · MYGN · announced Nov 1, 2022
Announced
Nov 1, 2022
Closed
Nov 1, 2022
Economics
Cash()
Pre-deal · pre-deal mark: 2022, year precision · Myriad Genetics press release — Gateway Genomics acquisition, 2022
$67.5M tuck-in acquisition (Myriad Genetics press release)
Target
Gateway Genomics
Diagnostics · Diagnostic / genomic
HQ San Diego, CA · Founded 2016
Consumer genetic testing — SneakPeek early gender DNA test (detects baby gender at 6 weeks with 99% accuracy); 750K+ parents served, 20%+ CAGR
- Globe Newswire — Myriad Genetics press release (Nov 1, 2022)
- Myriad Genetics investor relations
Acquirer
Myriad Genetics (MYGN)
Diagnostics
HQ Salt Lake City, UT
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
SneakPeek early gender test (99% accuracy at 6 weeks) expands consumer prenatal access — 750K+ parents served, 20%+ CAGR, 4M+ annual website visitors create funnel to clinical screening
Evidence ladder
Secondary (press / IR)
Globe Newswire — Myriad Genetics press release (Nov 1, 2022)
Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/899923/000089992322000137/mygn-20221101.htm
Open source
Limitations
- $67.5M tuck-in acquisition (Myriad Genetics press release)
- Pre-deal valuation sourced from: Myriad Genetics press release — Gateway Genomics acquisition, 2022. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Diagnostics
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| PreventionGenetics | Exact Sciences | Jan 9, 2022 | same evidence class |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| Thrive Earlier Detection | Exact Sciences | Oct 27, 2020 | ||
| Igenomix | Vitrolife | Jul 8, 2021 |
Other verified deals by Myriad Genetics
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| Counsyl | Myriad Genetics | May 28, 2018 | Diagnostics | |
| Sividon Diagnostics | Myriad Genetics | May 31, 2016 | Breast Health |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Gateway Genomics (Diagnostics). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.